Cancer Chemotherapy and Pharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma
ConclusionWe provide the data showing that PEG-LD 50  mg/m2 combined with cisplatin 100  mg/m2 demonstrated an acceptable safety profile and promising clinical activity in advanced osteosarcoma, which merits further evaluation in phase II studies.Trial registrationChiCTR1900021550. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 13, 2022 Category: Cancer & Oncology Source Type: research

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach
ConclusionSimulations showed a single G ‐CSF administration 48 h after the end of each eribulin injection seems to be the optimal schedule to reduce eribulin‐induced neutropenia. However, the new administration scheme should be tested in real life to evaluate its pertinence.Trial registrationEudract 2015-001753-32, 2015/01/26. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 8, 2022 Category: Cancer & Oncology Source Type: research

Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway
ConclusionAnlotinib exerts anti-glioblastoma activity possibly through the JAK2/STAT3/VEGFA signaling pathway. TMZ potentiated the anti-glioblastoma effect of anlotinib via the same signaling pathway, indicating the potential application of anlotinib as a treatment option for glioblastoma. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 8, 2022 Category: Cancer & Oncology Source Type: research

Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies
ConclusionOur results offer a promising role of combination therapies in cancer therapy as well as angiogenesis. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 6, 2022 Category: Cancer & Oncology Source Type: research

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis
ConclusionAn association between the ABCB1 C3435T (rs1045642), ABCB1 G2677T/A (rs2032582) polymorphism and risk of adverse effects of docetaxel was found by our meta-analysis. Namely, the TT homozygotes of the ABCB1 C3435T polymorphism may be associated with the risk of hematological toxicity. ABCB1 G2677T T(A)/T(A) genotype may be associated with the fluid retention.Trail registrationPROSPERO 2020 CRD42020203132. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 6, 2022 Category: Cancer & Oncology Source Type: research